Revlimid (lenalidomide) is neither traditional chemotherapy nor immunotherapy in the classic sense. It belongs to its own drug class called immunomodulatory agents, or IMiDs. Its FDA label describes it as “an immunomodulatory agent with antiangiogenic and antineoplastic properties,” which means it works through a combination of mechanisms: boosting the immune system, starving tumors of blood supply, and directly triggering cancer cell death. That blend is why it doesn’t fit neatly into either category.
Why Revlimid Isn’t Traditional Chemotherapy
Traditional chemotherapy drugs are cytotoxic, meaning they kill rapidly dividing cells throughout the body without much discrimination. That’s why conventional chemo causes widespread side effects like hair loss and severe nausea. Revlimid works differently. Instead of broadly poisoning fast-growing cells, it targets a specific protein inside cells and reprograms the body’s own protein-disposal system to destroy molecules that cancer cells depend on. It’s taken as an oral capsule rather than delivered through an IV infusion, and its side effect profile, while serious, looks quite different from classical chemotherapy.
That said, you’ll sometimes see Revlimid grouped under “chemotherapy” on hospital intake forms or insurance paperwork. This is a catch-all usage of the word, not a reflection of how the drug actually works. In pharmacology, Revlimid is classified separately from cytotoxic agents.
How Revlimid Works at the Molecular Level
Revlimid acts as a kind of molecular glue. It binds to a protein called cereblon, which is part of the cell’s natural recycling machinery. Normally, cereblon tags damaged or unneeded proteins for destruction. When Revlimid attaches to cereblon, it changes the shape of that protein just enough to trick it into grabbing new targets, specifically two transcription factors that multiple myeloma cells need to survive. Once tagged, those transcription factors get broken down by the cell’s own disposal system, and the myeloma cell dies.
In a different cancer, myelodysplastic syndromes with a specific chromosome deletion, Revlimid redirects the same recycling system toward a different target protein. Because the affected cells already have only one working copy of the gene that makes that protein, they’re especially vulnerable when Revlimid accelerates its destruction. This selectivity is part of what makes the drug effective in specific cancers rather than across the board.
The Immune-Boosting Side of Revlimid
Revlimid does have genuine immunotherapy-like properties, which is why the “immunomodulatory” label exists. It enhances the activity of natural killer (NK) cells, a type of immune cell that patrols for abnormal cells. Specifically, it increases the production of granzyme B, a molecule NK cells use to punch holes in cancer cells and trigger their death. It also boosts production of interferon-gamma, a signaling molecule that helps coordinate the immune response against tumors.
These immune effects are particularly notable when Revlimid is combined with antibody therapies like rituximab. In lab studies, Revlimid enhanced NK cells’ ability to kill antibody-coated tumor cells by increasing the expression of death-triggering molecules on the NK cell surface. When combined with immune-stimulating signals, NK cells expressing these killing molecules jumped from roughly 5% to 25%. Importantly, Revlimid doesn’t activate NK cells on its own in a nonspecific way. The immune boost requires both an antibody targeting the tumor and additional immune signaling, which means it amplifies a directed immune response rather than causing generalized immune activation.
Blood Vessel Starving: The Third Mechanism
Revlimid also blocks the growth of new blood vessels that tumors need to feed themselves. It does this by interfering with the signaling pathway that a key growth factor uses to stimulate blood vessel formation. In lab comparisons, lenalidomide was at least 10 times more potent than its predecessor, thalidomide, at disrupting the formation of tube-like blood vessel structures. This anti-angiogenic effect cuts off the tumor’s supply lines, slowing its growth from yet another angle.
FDA-Approved Uses
Revlimid is approved to treat several blood cancers. Its primary use is in multiple myeloma, where it’s prescribed both as a frontline treatment (combined with dexamethasone for patients who aren’t candidates for stem cell transplant) and as maintenance therapy after transplant. It was first approved for myeloma in 2006 for patients who had already tried at least one other treatment, and its approved uses have expanded since then.
Beyond myeloma, Revlimid is approved for myelodysplastic syndromes (a group of bone marrow disorders) and mantle cell lymphoma, as well as certain types of non-Hodgkin lymphoma including follicular lymphoma and marginal zone lymphoma, where it’s typically paired with rituximab.
What Treatment Looks Like
For multiple myeloma, the standard starting dose is 25 mg once daily, taken by mouth for 21 days followed by 7 days off, in repeating 28-day cycles. For myelodysplastic syndromes, the dose is lower at 10 mg daily. Because it’s an oral capsule taken at home, the treatment experience feels very different from sitting in an infusion chair for hours, which is another reason patients wonder whether it’s “really” chemotherapy.
Side Effects to Expect
Revlimid’s most common side effects in myeloma patients include fatigue, diarrhea, constipation, muscle cramps, and skin rash. These overlap somewhat with traditional chemo side effects, but the more distinctive risks involve blood counts and clotting.
Low blood cell counts are the most significant concern. In myeloma patients on maintenance therapy, up to 59% experienced severe drops in neutrophils (infection-fighting white blood cells), and up to 38% had severe drops in platelets (cells that help blood clot). For myelodysplastic syndromes, severe blood count problems affected 80% of patients in clinical studies. These numbers are high, and regular blood monitoring is a routine part of treatment.
Blood clots are another notable risk. Among myeloma patients treated with Revlimid and dexamethasone, 7.4% developed deep vein thrombosis and 3.7% developed pulmonary embolism, roughly double the rates seen in patients not taking the drug. Preventive blood thinners are commonly prescribed alongside Revlimid for this reason. In lymphoma patients treated with Revlimid and rituximab, clot rates were lower, around 3.4%.
So What Should You Call It?
The most accurate term is immunomodulatory drug, or IMiD. If you’re filling out forms or explaining your treatment and need a simpler label, “targeted therapy” or “immunomodulatory therapy” captures its nature better than either chemotherapy or immunotherapy alone. It borrows from both worlds: it kills cancer cells directly (like chemo) and rallies the immune system (like immunotherapy), but it does both through a unique mechanism that earned it a classification of its own.